Bitcoin Holdings of Japanese Listed Company Metaplanet Surpass El Salvador
On May 12, it was reported that Simon Gerovich, CEO of the Japanese listed company Metaplanet, stated on social media that after acquiring an additional 1,241 Bitcoins today, Metaplanet's total Bitcoin holdings have increased to 6,796, surpassing El Salvador's holdings (6,714 Bitcoins). It is known that the CEO of Metaplanet was formerly the head of the equity derivatives department at Goldman Sachs. Since 2013, he has been operating Metaplanet (formerly Red Planet Japan Inc.) as a hotel developer. However, the pandemic led to an economic slowdown, forcing the company to close most of its hotels, leaving only one in operation. When the market value once fell to about $15 million, UTXO Management invested in the company, leading it to adopt a Bitcoin strategy. Since then, the number of Metaplanet shareholders has grown to nearly 50,000, and its market value has soared to $2 billion, making it the best-performing stock among companies with a global market value exceeding $250 million in 2024. Recently, it announced the largest public equity financing in Asia's history, planning to raise $750 million to purchase Bitcoin.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

